Researchers have reported unusual electronic signals in human bodies and changes in blood measurements following supplementation with a natural mineral. Two studies published two years apart now raise questions about graphene oxide, silicon-based nanotechnology and what scientists can actually prove.

What if researchers discovered unusual electronic signals coming from the human body, then reported that those signals declined dramatically following treatment with a naturally occurring mineral?

That is the controversy surrounding GrapHene Oxidative Silicon Technology, better known as GHOST.

The name sounds like something pulled from a classified military research project. Yet the technology described in the research draws on genuine scientific fields involving graphene, silicon semiconductors, nanotechnology and bioelectronics.

In October 2026, researcher Caroline A. Mansfield published a study reporting unusual semiconductor-like electronic responses in 22 human participants.

The findings were striking.

Following 63 days of supplementation with a clinoptilolite-based mineral product, researchers reported a 79% reduction in average electronic signal intensity.

But the October investigation did not emerge in isolation.

Two years earlier, Robert O. Young and Caroline A. Mansfield had published another study examining whether a similar mineral supplement could reduce measurements associated with graphene oxide, microplastics, heavy metals and other substances in human blood.

______________________________________________

🔴 Help keep this independent voice alive and uncensored.

Support independent journalism and help keep Chris Wick News going.

👉 Support Chris Wick on GoFundMe

Together, the publications present a controversial research narrative.

The first study reported changes in blood-based measurements.

The second reported changes in electronic signals.

Neither conclusively established that engineered graphene-silicon structures were present in participants or physically removed by the supplement.

That distinction is essential to understanding what the research actually reveals.

The First Investigation: Young and Mansfield’s 2024 Study

On August 23, 2024, Robert O. Young and Caroline A. Mansfield published a paper in Acta Scientific Medical Sciences examining a commercial mineral supplement called MasterPeace Zeolite Z.

The study carried the title:

MasterPeace Zeolite Z Pilot Study Found to be Safe and Effective in Removing Nano and Micro Toxic Forever Chemicals, Heavy Metals, Micro Plastics and Graphene and Aluminum Found in the Human Body Cells and Fluids.

The researchers recruited three participants: two women and one man, aged between 57 and 60.

Their objective was to investigate whether daily supplementation could reduce measurements associated with several substances, including graphene oxide.

The participants underwent blood testing before beginning supplementation, followed by additional testing after 35 and 90 days.

Researchers used a testing approach described as intracellular electrical capacity, or iEC, to assess the reported concentrations of selected substances.

The supplement contained nano-sized clinoptilolite zeolite combined with a mineral preparation described as sea plasma.

Participants were instructed to take at least five drops twice daily for 90 days.

The study did not include a placebo group.

Nevertheless, the researchers reported substantial changes in several measured indicators.

What the 2024 Study Reported About Graphene Oxide

The researchers presented individual results for graphene oxide measurements in all three participants.

According to the published data, the reported graphene oxide measurements changed as follows:

These figures reproduce the numerical results reported by the research programme. The percentages compare baseline and day-90 values.

The largest reported decline occurred in Subject 2, whose graphene oxide indicator fell by approximately 87%.

Subject 1 showed a reduction of approximately 74%.

Subject 3 demonstrated a smaller decline of approximately 27%.

These observations formed part of the researchers’ argument that clinoptilolite supplementation might influence substances they associated with cellular toxicity.

However, there is an important limitation.

The reported iEC results do not independently establish that graphene oxide was chemically identified in the participants’ blood.

The paper did not demonstrate graphene oxide removal using independently validated chemical identification and clearance measurements.

Consequently, the findings cannot be treated as definitive proof that the supplement eliminated graphene oxide from human tissues.

They are preliminary observations requiring independent verification.

The Researchers Also Examined Microplastics and Forever Chemicals

The 2024 investigation extended beyond graphene oxide.

Young and Mansfield examined reported measurements associated with several additional substances, including:

• Perfluorooctanoic acid, commonly known as PFOA.
• Perfluorooctane sulfonate, or PFOS.
• Polyethylene and polypropylene, two widely used plastics.
• Aluminum and iron.
• Glyphosate, lindane and phosgene.

The published results included reductions in several of these indicators over the 90-day supplementation period.

The product manufacturer’s published summary described an average reduction of approximately 41.7% across the substances and participants it evaluated.

It also highlighted individual reductions of approximately 93.6% for PFOA, 76.9% for polyethylene and 88.8% for polypropylene.

Those figures are significant as reported observations.

But the study involved only three people.

There was no untreated comparison group, and the findings were based on a testing method whose suitability for identifying and quantifying these diverse substances requires independent validation.

A change in a measurement does not automatically establish that a specific chemical was physically removed from the body.

For that conclusion, researchers would need validated analytical methods, appropriate controls and evidence of the material’s elimination.

October 2026: The GHOST Investigation Expands the Research

Two years after the initial pilot study, Caroline Mansfield published a substantially larger investigation.

The October 5, 2026 paper was titled:

GrapHene Oxidative Silicon Technology (GHOST™) Found in Human Tissues and Removed by Mineralised Nano-Sized Clinoptilolite.

Published in Acta Scientific Medical Sciences, the study examined 22 participants between the ages of 26 and 75.

Unlike the earlier investigation, which focused on blood-based measurements, the 2026 research used electronic detection equipment.

The researchers employed an EDD-24XT nonlinear junction detector.

Such devices are designed to identify nonlinear electronic responses, including signals associated with semiconductor junctions.

At the beginning of the investigation, all 22 participants produced responses classified by the detector as potentially consistent with silicon-associated semiconductor behaviour.

The researchers subsequently monitored the participants during a 63-day supplementation period involving MasterPeace Zeolite Z.

The results attracted attention because of the magnitude of the reported changes.

Average signal intensity scores reportedly declined from approximately 1,340 to 277.

That represented a reduction of approximately 79%.

The average number of active detection locations decreased from approximately 21 to seven per participant.

That represented a reduction of approximately 67%.

The average signal intensity at remaining detection locations also fell by approximately 38%.

The findings suggested that the detector responses changed considerably during the supplementation period.

But the equipment could not establish the chemical identity of the material, if any, responsible for those responses.

The researchers acknowledged this limitation and called for further investigation.

The Connection Between the Two Studies

The relationship between the 2024 and 2026 publications is particularly interesting.

Both investigations examined the same commercial clinoptilolite-based supplement.

Both reported substantial changes in measurements following supplementation.

And both explored questions involving substances or signals that the researchers associated with nanotechnology.

However, the studies measured fundamentally different things.

The 2024 investigation used blood-based iEC testing to assess indicators attributed to graphene oxide and other substances.

The 2026 investigation used electronic detection equipment to measure nonlinear electromagnetic responses.

The later study therefore did not independently confirm the earlier study’s graphene oxide findings.

Nor did the earlier study establish that the electronic signals reported in 2026 originated from graphene oxide or silicon nanotechnology.

The two publications may provide a basis for additional research, but their results cannot simply be combined into proof of a single biological phenomenon.

That is the missing link.

What Exactly Is GHOST Technology?

GHOST is an acronym for GrapHene Oxidative Silicon Technology.

The framework discussed in the October paper connects several areas of legitimate scientific research.

Graphene is a carbon-based material with unusual electrical and mechanical properties.

Graphene oxide is a chemically modified form of graphene containing oxygen-bearing groups.

Silicon is a semiconductor material widely used in electronic components.

Scientists have investigated combinations of advanced carbon materials, silicon nanowires and miniature electronic structures for biomedical applications.

Potential uses include biological sensors, neurological interfaces and technologies capable of monitoring electrical activity in living tissue.

These developments are real.

But the existence of graphene-based bioelectronics does not demonstrate that an unidentified GHOST system has been distributed throughout the human population.

It also does not establish that unusual electronic signals detected near the body originate from implanted nanotechnology.

To prove that claim, investigators would need to recover or directly characterize the suspected material.

That evidence has not been established by the two studies.

Clinoptilolite: The Mineral at the Centre of Both Investigations

Clinoptilolite is a naturally occurring zeolite mineral.

Its crystalline structure contains microscopic channels and cavities that can interact with certain ions and molecules.

These properties make it useful in applications involving filtration, adsorption and ion exchange.

Researchers have investigated whether particular purified clinoptilolite preparations can influence the absorption of selected substances in humans.

A randomized clinical study published in Scientific Reports in 2021 found that a purified clinoptilolite preparation reduced gastrointestinal absorption of an administered lead isotope.

That finding provides evidence for a specific effect under controlled conditions.

But reducing lead absorption in the digestive tract is not equivalent to extracting graphene oxide, microplastics or semiconductor structures from human tissues.

The effectiveness of a material in one application does not automatically establish its effectiveness in another.

Furthermore, clinoptilolite products differ in purity, particle size and formulation.

Evidence involving one preparation cannot necessarily be applied to every commercially available supplement.

The possibility that clinoptilolite could influence certain biological processes deserves scientific investigation.

Its ability to remove GHOST technology, however, remains unproven.

The Scientific Questions That Remain Unanswered

The two publications raise several important questions.

First, were the substances measured in the 2024 study correctly identified and quantified?

Second, what produced the semiconductor-like electronic signals reported in the 2026 investigation?

Third, could independent laboratories reproduce the findings using validated equipment and blinded testing?

Fourth, would participants receiving a placebo show similar changes over the same period?

And finally, could researchers directly demonstrate the physical removal of identified nanomaterials from human tissues?

These are not minor technical objections.

They are fundamental requirements for establishing a new medical or scientific discovery.

Without those answers, the reported findings remain preliminary.

Why Independent Research Matters

The commercial supplement examined in both studies is marketed for detoxification.

That creates a particular need for independent evaluation.

Studies involving commercial products should clearly disclose relevant financial interests and allow outside researchers to reproduce their findings.

The larger the reported benefit, the more important rigorous verification becomes.

An 87% reduction in a purported graphene oxide measurement sounds impressive.

A 79% reduction in an electronic signal score is equally striking.

But neither percentage establishes the underlying cause of the change.

Researchers must first demonstrate that their measurements accurately identify what they claim to measure.

Only then can they determine whether a treatment actually removes or alters the material.

Until such evidence exists, the findings should not be used to promote clinoptilolite as a proven treatment for graphene oxide exposure or alleged implanted nanotechnology.

The Larger Question: How Much Do We Really Know About Nanotechnology and Human Health?

Nanotechnology is advancing rapidly.

Researchers are developing materials that interact with cells, biological membranes and electrical signals.

Graphene-based materials are being investigated for potential medical applications, including biosensors and drug delivery.

Some experimental studies have identified possible toxic effects associated with particular graphene materials and exposure conditions.

Other research has reported relatively limited short-term effects under carefully controlled circumstances.

For example, a 2024 study published in Nature Nanotechnology examined controlled graphene oxide inhalation in 14 healthy volunteers.

The researchers found that the exposure conditions were generally well tolerated, although the study could not establish the safety of every graphene material or long-term exposure.

This is why scientific precision matters.

Graphene oxide is neither automatically harmless nor automatically evidence of a hidden technological threat.

Its biological effects depend on the material, exposure route, concentration and other factors.

Those uncertainties deserve investigation without turning unverified possibilities into established facts.

Final Thought: Two Studies, Extraordinary Claims and a Missing Piece of Evidence

Robert O. Young and Caroline A. Mansfield’s 2024 investigation reported changes in blood-based measurements associated with graphene oxide and several other substances.

Caroline Mansfield’s October 2026 investigation subsequently reported substantial reductions in semiconductor-like electronic responses following supplementation with the same commercial mineral product.

The findings are unusual.

They also raise questions worth examining.

But the central issue remains unresolved.

Neither study conclusively demonstrated the presence of a graphene-silicon electronic network inside human tissues.

Neither established that such a network was physically removed through clinoptilolite supplementation.

And neither provided the controlled, independently replicated evidence necessary to establish a new medical treatment.

That does not mean researchers should abandon the subject.

It means the next investigation must go further.

Direct material identification, validated laboratory testing, placebo controls and independent replication would help determine whether the reported observations represent a genuine biological discovery or limitations in the measurement methods.

The public deserves answers about emerging nanotechnology and its potential effects on human health.

But those answers must be built on evidence rather than speculation.

Because when scientists report extraordinary findings inside the human body, the most important question is not how frightening the discovery sounds.

It is whether the evidence proves what the researchers believe they have found.

SOURCES

1. Acta Scientific Medical Sciences — 2026 GHOST Study

Caroline Mansfield. GrapHene Oxidative Silicon Technology (GHOST™) Found in Human Tissues and Removed by Mineralised Nano-Sized Clinoptilolite. October 5, 2026.

https://www.actascientific.com/ASMS/ASMS-10-2293.php

2. Acta Scientific Medical Sciences — 2024 Pilot Study

Robert O. Young and Caroline A. Mansfield. MasterPeace Zeolite Z Pilot Study Found to be Safe and Effective in Removing Nano and Micro Toxic Forever Chemicals, Heavy Metals, Micro Plastics and Graphene and Aluminum Found in the Human Body Cells and Fluids. August 23, 2024.

https://drrobertyoung.com/wp-content/uploads/2024/10/ASMS-08-1913.pdf

3. Scientific Reports — Nature Portfolio

Concomitant Oral Intake of Purified Clinoptilolite Tuff (G-PUR) Reduces Enteral Lead Uptake in Healthy Humans. 2021.

https://www.nature.com/articles/s41598-021-94245-x

4. Nature Nanotechnology

First-in-Human Controlled Inhalation of Thin Graphene Oxide Nanosheets to Study Acute Cardiorespiratory Responses. 2024.

https://www.nature.com/articles/s41565-023-01572-3